# US 5,350,755 A · Compounds and methods for treating hyperproliferative skin disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,350,755 A
- Document ID: US5350755A
- Status: Granted
- Kind: A
- Application number: 07/917,925
- Filed: 1992-07-21
- Granted: 1994-09-27
- Earliest claimed: 1986-12-05
- Assignees: Schering Corporation
- Inventors: David J. Blythin
- Web page: https://patentgrep.com/patent/US5350755A

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating hyperproliferative skin disease in a mammal with substituted spiro pyridine derivatives is disclosed. The compounds may be administered topically or by other conventional routes of administration.

## Claims

### Claim 1

A method of treating psoriasis or eczema in a mammal, comprising administering in combination with a pharmaceutically acceptable carrier a compound having the structural formula: ##STR8## wherein n is 1, 2 or 3; R.sup.4 and R.sup.5 are hydrogen, methyl or ethyl and Q' is hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, nitro, alkoxy having from 1 to 6 carbon atoms, halogen, nitro, having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, S(O).sub.m -R.sup.a {wherein m is 0, 1 or 2 and R.sup.a is alkyl having from 1 to 6 carbon atoms}, NHSO.sub.2 R.sup.a {wherein R.sup.a is defined herein}, NHSO.sub.2 CF.sub.3, SO.sub.2 NH.sub.2, COR.sup.b {wherein R.sup.b is OH, NH.sub.2 or OR.sup.a (wherein R.sup.a is defined herein)}, O-B-COR.sup.b {wherein B is alkanediyl having from 1 to 4 carbon atoms and R.sup.b is defined herein}, or NHCOR.sub.c {wherein R.sup.c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR.sup.d (wherein R.sup.d is hydroxy or alkoxy having from 1 to 6 carbons atoms) or NHR.sup.e (wherein R.sup.e is hydrogen or alkyl having from 1 to 6 carbon atoms)}.

### Claim 2 (depends on 1)

The method defined in claim 1 wherein the compound is:
1'-phenylspiro[cyclopentane-1,3'-(1,8)naphthyridine]-2', 4'-(1'H)-dione;
1'-(4-methylphenyl)spiro[cyclopentane-1,3'-(1,8)-naphthyridine]-2', 4'-(1'H)-dione;
1'-(4-chlorophenyl)spiro[cyclopentane-1,3'-(1,8)-naphthyridine]-2', 4'-(1'H)-dione;
1'-(3,4-dichlorophenyl)spiro[cyclopentane-1,3'-(1,8)-naphthyridine]-2', 4'-(1'H)-dione;
1'-(3-chlorophenyl)spiro[cyclopentane-1,3'-(1,8)-naphthyridine]-2', 4'-(1'H)-dione;
1'-(3-methoxyphenyl)spiro[cyclopentane-1,3'-(1,8)-naphthyridine]-2', 4'-(1'H)-dione; or
1'-(4-hydroxyphenyl)spiro[cyclopentane-1,3'-(1,8)-naphthyridine]-2', 4'-(1'H)-dione.

### Claim 3 (depends on 2)

The method of claim 2 wherein the compound administered is 1'-(3-chlorophenyl) spiro[cyclopentane-1,3'(1,8)naphthyridine]-2', 4'-(1'H)-dione

### Claim 4 (depends on 2)

The method as defined in claim 2 wherein the compound of formula I is administered topically.

### Claim 5 (depends on 1)

The method as defined in claim 1 wherein the compound is administered as a pharmaceutical composition comprising the compound of formula I in combination with a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

The method as defined in claim 5 wherein the pharmaceutical composition is an ointment.

### Claim 7 (depends on 5)

The method as defined in claim 5 wherein the pharmaceutical composition is a cream.

### Claim 8 (depends on 5)

The method as defined in claim 5 wherein the pharmaceutical composition is a lotion.

### Claim 9 (depends on 5)

The method as defined in claim 5 wherein the pharmaceutical composition is an aerosol.